Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
about
Oligometastatic prostate cancer: Metastases-directed therapy?The Utility of Molecular Imaging in Prostate CancerA comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancerTarget Definition in Salvage Radiotherapy for Recurrent Prostate Cancer: The Role of Advanced Molecular ImagingRepeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrenceOligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options.Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialThe biology and treatment of oligometastatic cancer.Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT)Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective StudyRadiotherapy cannot prolong overall survival of young prostate cancer patients with bone metastasesClinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach.Advances in local and ablative treatment of oligometastasis in prostate cancer.Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations.The Role of Hypofractionated Radiotherapy in Prostate Cancer.The role of metastasis-directed therapy and local therapy of the primary tumor in the management of oligometastatic prostate cancer.Metastasectomy of Abdominal Wall Lesions due to Prostate Cancer Detected Through PET/CT Gallium 68-PMSA: First Case Report.What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?Stereotactic body radiation therapy for the treatment of oligoprogression on androgen receptor targeted therapy in castration-resistant prostate cancer.(68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer : Early efficacy after primary therapy.(18)F-choline PET/CT for early detection of metastases in biochemical recurrence following radical prostatectomy.Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy.[Sub-threshold prostate-specific antigen levels after resection of metachronous pulmonary metastases].Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.Stereotactic ablative body radiotherapy in patients with prostate cancerEmerging role of cytoreductive prostatectomy in patients with metastatic diseaseWorth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancerThe efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer
P2860
Q26740069-6F3594DA-C15C-43EF-BBC1-6F2EE559C4AAQ26764746-1D804680-3FBC-4B14-842D-FA7B47C7D40AQ27000180-F422A0FA-815C-4368-A88D-9554CF5A5FC6Q28074669-5772477B-0443-4A77-827F-98C27E53FA4CQ33789117-1DFA5E19-EBDC-44B9-8060-8EDEF75974A7Q34748629-52A3C7EA-71D8-4F1F-A0EE-DF244FF6EAFCQ35253783-F72F9A35-16BC-47A2-A846-21955974B522Q35832153-060D4C21-5463-481E-B1B5-680863AC6AB4Q36377961-76409817-297D-4F97-B726-EEA7B643A257Q36581142-0E3D55A6-C7E3-4615-BF04-1A74DA6D04B9Q36842274-C82DF531-DA4B-49D2-8E08-706AFB6B2796Q37187233-952F6262-F319-49F4-A55E-DAC6F3B97EC3Q38243113-B4E224A5-5D60-4B74-AFDA-5307E6FB72B4Q38977428-CE877526-A55E-4AF5-A618-D2106A642C77Q39200876-84F1B464-A6BD-4169-AF48-AF055075B826Q41566002-DB8D2605-A7DF-45DD-A604-E900D94091FDQ42316583-9A2493FF-B957-483C-ACB0-9A1DC413EF97Q47904167-EE55AF6B-B89F-4C8D-85FB-A2793779996CQ49218636-98FF3BA4-98FA-4648-9570-5C6DD5E03F0CQ51715242-384DD1D0-4920-45BA-AAD9-F332BB26086CQ53018341-4F14308A-7033-43A6-B8AD-BA72D88D651BQ53267613-24E1FFDD-1921-43E9-A5F9-41647C265EECQ53402018-49374DCF-CEDE-42FE-80C8-1B7FF87F6B09Q55379783-AF080F01-162E-4B5F-961B-54813EF00F03Q57112486-07ED5CDC-6832-4E54-B611-84E598553B7CQ58562228-FB3210B7-9E12-405D-A2B9-BC829C51E701Q58706995-10E157B1-63B3-4A9C-9C85-E25B5E6F4236Q58802712-C6E2E045-6AF3-40C3-853D-975D898401EF
P2860
Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Androgen deprivation and high- ...... nal and/or distant metastases.
@en
Androgen deprivation and high- ...... nal and/or distant metastases.
@nl
type
label
Androgen deprivation and high- ...... nal and/or distant metastases.
@en
Androgen deprivation and high- ...... nal and/or distant metastases.
@nl
prefLabel
Androgen deprivation and high- ...... nal and/or distant metastases.
@en
Androgen deprivation and high- ...... nal and/or distant metastases.
@nl
P2093
P2860
P1433
P1476
Androgen deprivation and high- ...... nal and/or distant metastases.
@en
P2093
Damien C Weber
Hansjoerg Vees
Michel Rouzaud
Osman Ratib
Philippe Nouet
Raymond Miralbell
Sandra Jorcano
Thomas Zilli
Ulrike Schick
P2860
P304
P356
10.3109/0284186X.2013.764010
P577
2013-04-02T00:00:00Z